Anticancer effects and underlying mechanisms of HJC0152, a small-molecule STAT3 inhibitor, on tumor invasion and migration in human head and neck squamous cell carcinoma
-
摘要:
目的 探讨新型信号转导和转录活化因子3（signal transducer and activator of transcription，STAT3）抑制剂HJC0152对人头颈部鳞癌（head and neck squamous cell carcinoma，HNSCC）细胞株侵袭和迁移能力的影响及可能机制。 方法 实验分为二甲基亚砜（DMSO）组和HJC0152组。Western blot检测细胞总蛋白中STAT3、p-STAT3 Tyr705/Ser727、MMP-2/9、N/E-cadherin、TWIST1和vimentin蛋白表达水平及核浆蛋白中的STAT3和p-STAT3 Tyr705/Ser727蛋白表达水平；划痕实验和Transwell实验检测细胞侵袭、迁移能力；免疫荧光实验观察N/E-cadherin蛋白的表达和亚细胞定位。 结果 HJC0152组细胞总蛋白和核浆蛋白p-STAT3 Tyr705表达水平均受到显著抑制，而STAT3、p-STAT3 Ser727未见明显变化；总蛋白MMP-2/9、N-cadherin、TWIST1和vimentin表达水平降低，E-cadherin水平升高。HJC0152组细胞向划痕中央移动的距离明显短于DMSO组，通过Transwell小室聚碳酸酯膜的细胞较DMSO组也显著减少。 结论 HJC0152可有效抑制头颈鳞癌细胞STAT3 Tyr705的磷酸化，阻碍其发挥转录因子的作用，抑制其下游基因表达，从而干预HNSCC侵袭和迁移能力。 Abstract:This study aims to explore the anticancer effects and potential mechanisms of HJC0152, a novel STAT3 inhibitor, on the invasion and migration capacities of human head and neck squamous cell carcinoma (HNSCC) cell lines in vitro. Methods Cells were divided into two groups, the dimethyl sulfoxide (DMSO) group and the HJC0152 group in which HNSCC cell lines UM-1 and SCC-15 were treated with DMSO or HJC0152 for 24 h. The total expression levels of STAT3, p-STAT3 (Tyr705/Ser727), MMP-2/9, N/E-cadherin, TWIST1, and vimentin; and the cytoplasm and nuclear expression levels of STAT3 and p-STAT3 (Tyr705/Ser727) were detected by Western blot assay.Wound healing and Transwell assays were employed to detect the invasion and migration abilities of the UM-1 and SCC-15 cells. The expression and location of N/E-cadherin were visualized by immunofluorescence staining. Results Western blot indicated that the total expression of p-STAT3 (Tyr705), MMP-2/9, N-cadherin, TWIST1, and vimentin were significantly declined and that E-cadherin was remarkably elevated in the HJC0152 group cells compared with that of the DMSO group, with no difference in STAT3 or p-STAT3 (Ser727). Cytoplasm and nuclear STAT3 (Tyr705) were also inhibited by HJC0152. Wound healing and Transwell assays indicated that tumor invasion and migration capacities were impressively attenuated in the HJC0152 group cells compared to that of the DMSO group. Conclusion HJC0152 suppresses the phosphorylation of STAT3 at Tyr705 in the HNSCC cell lines, leading to impair transcription activity, deplete expression levels of target genes, and subsequently inhibit migration and invasion capabilities of HNSCC. -
图 1 MTT法测定UM-1和SCC-15细胞系中HJC0152的半数抑制率
Figure 1. IC50 of HJC0152 in UM-1 and SCC-15 determined by MTT
图 2 HJC0152对STAT3蛋白活性位点磷酸化的影响
Figure 2. Effect of HJC0152 on STAT3 phosphorylation level
图 3 HJC0152对人头颈部鳞癌迁移侵袭能力的影响
Figure 3. Effect of HJC0152 on migration and invasion capacities in human HNSCC
图 4 HJC0152对侵袭性和EMT相关标志蛋白表达的影响
Figure 4. Effect of HJC0152 on invasion and the expression of EMT biomarkers
-
[1] Lam L, Logan RM, Luke C. Epidemiological analysis of tongue cancerin South Australia for the 24-year period, 1977-2001[J]. Aust Dent J, 2006, 51(1):16-22. doi: 10.1111/j.1834-7819.2006.tb00395.x [2] Jacobs C, Lyman G, Velez-Garcia E, et al. A phase Ⅲ randomized studycomparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck[J].J Clin Oncol, 1992. 10(2):257-263. doi: 10.1200/JCO.1992.10.2.257 [3] Shen DW, Pouliot LM, Hall MD, et al. Cisplatin resistance: a cellular selfdefense mechanism resulting from multiple epigenetic and genetic changes[J]. Pharmacol Rev, 2012, 64(3):706-721. doi: 10.1124/pr.111.005637 [4] Duan Z, Foster R, Bell DA, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer[J].Clin Cancer Res, 2006, 12(17):5055-5063. doi: 10.1158/1078-0432.CCR-06-0861 [5] Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer:new and unexpected biological functions[J]. Nat Rev Cancer, 2014, 14(11):736-746. doi: 10.1038/nrc3818 [6] Chen J, Wang J, Lin L, et al. Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer[J]. Mol Cancer Ther, 2012, 11(2):277-287. doi: 10.1158/1535-7163.MCT-11-0648 [7] Tong ZT, Cai MY, Wang XG, et al. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin[J]. Oncogene, 2012, 31(5):583-594. https://www.ncbi.nlm.nih.gov/pubmed/21685935 [8] Chen H, Yang Z, Ding C, et al. Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents[J]. ACS Med Chem Lett, 2013, 4(2):180-185. doi: 10.1021/ml3003082 [9] Rosenthal EL, Matrisian LM. Matrix metalloproteases in head and neck cancer[J]. Head Neck, 2006, 28(7):639-648. doi: 10.1002/(ISSN)1097-0347 [10] Castellanos JA, Merchant NB, Nagathihalli NS. Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells[J]. Onco Targets Ther, 2013, 6:1261-1267. https://www.ncbi.nlm.nih.gov/pubmed/24049451 [11] Cho KH, Jeong KJ, Shin SC, et al. STAT3 mediates TGF-beta1-induced TWIST1 expression and prostate cancer invasion[J]. Cancer Lett, 2013, 336(1):167-173. doi: 10.1016/j.canlet.2013.04.024 [12] Adachi M, Cui C, Dodge CT, et al. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma [J]. Oral Oncol, 2012, 48(12):1220-1226. doi: 10.1016/j.oraloncology.2012.06.006 [13] Smith A, Teknos TN, Pan Q. Epithelial to mesenchymal transition in head and neck squamous cell carcinoma[J]. Oral Oncol, 2013, 49(4):287-292. doi: 10.1016/j.oraloncology.2012.10.009 [14] Stepkowski SM, Chen W, Ross, JA, et al. STAT3: an important regulator of multiple cytokine functions[J]. Transplantation, 2008, 85(10):1372-1377. doi: 10.1097/TP.0b013e3181739d25 [15] Kijima T, Niwa H, Steinman RA, et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo[J]. Cell Growth Differ, 2002, 13(8):355-362. http://cgd.aacrjournals.org/cgi/content/abstract/13/8/355 [16] Stanam A, Love-Homan L, Joseph TS, et al. Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma[J]. Mol Oncol, 2015, 9(7):1371-1383. doi: 10.1016/j.molonc.2015.03.008 [17] Cai S, Zheng M, Chen L. Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma[J]. J Dermatol, 2005, 32(5):354-360. doi: 10.1111/jde.2005.32.issue-5 [18] Kamran MZ, Patil P, Gude RP. Role of STAT3 in cancer metastasis and translational advances[J]. Biomed Res Int, 2013:421821. https://www.hindawi.com/journals/bmri/2013/421821/abs/ [19] Wheeler SE, Suzuki S, Thomas SM, et al. Epidermal growth factor receptor variant Ⅲ mediates head and neck cancer cell invasion via STAT3 activation[J]. Oncogene, 2010, 29(37):5135-5145. doi: 10.1038/onc.2009.279 [20] Nijkamp MM, Span PN, Hoogsteen IJ, et al. Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients[J]. Radiother Oncol, 2011, 99(3):344-348 doi: 10.1016/j.radonc.2011.05.066 -
下载:
点击查看大图
图(5)
计量
- 文章访问数: 68
- HTML全文浏览量: 6
- PDF下载量: 5
- 被引次数: 0
